George Higginson

The integration of advanced technologies has become essential in the pharmaceutical sector to optimize processes and yield safe and effective healthcare solutions in a timely manner. Artificial Intelligence (AI) has emerged as a revolutionary force in the field, with its substantial impact on pharmaceutical research and development. This transformative technology is projected to generate significant economic value, driving innovation across various aspects of the sector. As pharmaceutical companies harness the potential of AI to streamline R&D processes and minimize costs, the industry stands on the brink of a technological breakthrough that promises to reshape the future of pharmaceutical innovation. Have you seen AI being utilized in pharmaceutical processes?

3

💊 Are you a leader in pharma development and considering outsourcing? Outsourcing can offer major advantages in pharma, but success starts with asking the right questions. Our latest blog outlines 5 essential considerations to guide your strategy and highlights how Synergy Scientific Solutions provides the flexibility, expertise and dedicated management support needed for optimal results. From improving agility to strengthening supply chain transparency, discover how Synergy can make outsourcing work for your unique goals. Read the full blog here 👇 https://bit.ly/3AsbKH3 #Pharma #Outsourcing #Science #SupplyChain #Pharmaceuticals

6

Clinical Trials Updates: Ascendis Pharma's Yorvipath Approved for Hypoparathyroidism Danish drugmaker Ascendis Pharma has secured FDA approval for Yorvipath to treat hypoparathyroidism, a rare endocrine disorder affecting an estimated 70,000 to 90,000 people in the US. This condition occurs when the parathyroid glands produce insufficient parathyroid hormone, leading to low calcium levels and symptoms like muscle cramps, numbness, and tingling. Yorvipath becomes the sole approved treatment for hypoparathyroidism in the US following the discontinuation of Takeda's Natpara. Ascendis anticipates launching Yorvipath in the first quarter of 2025, addressing a significant unmet medical need. https://lnkd.in/eJmh3Mph

3

Take a read of this article if you are thinking of adding to your teams in Jan-March 2025. There's also some helpful ideas that could improve your hiring approach all year round. Get ahead of the game, get organised and start now 😊 #drugdiscovery #biotech #hiring #recruitment #greattalent #2025

7

3 Comments

A significant increase in Scientific Advisor roles has been observed in Q1 of this year. If this trend continues, there will be a 118% rise compared to last year. 📈 Discover more data-driven insights in the latest report by Cpl Life Sciences and Vacancysoft: https://zurl.co/3AhQ #lifesciences #datainsights

2

🔬 Big News Alert! 🔬 🌟 FDA, EPA, and USDA join forces to streamline regulation for biotech products! 🌟 Interesting times ahead for the biotech industry as these agencies collaborate to simplify pathways to market while maintaining rigorous safety standards. How do you think this will shape the future of biotech? 💥 #Biotech #Regulation #Innovation #FDA #EPA #USDA

20

𝐈𝐬 𝐂𝐞𝐥𝐥 & 𝐆𝐞𝐧𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐭𝐡𝐞 𝐍𝐞𝐰 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫 𝐨𝐟 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐚𝐧𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬? Very interesting insight provided by Mansfield Advisors on the potential future for CGT. The CGT market has expanded from under $1 billion in 2018 to over $5.5 billion in 2023. It doesn't look like slowing down with FDA approvals doubling in the last five years and groundbreaking treatments like Yescarta and Zolgensma leading the way. Outsourced services like CDMOs and CROs are leading the way, creating exciting investment opportunities across raw materials, manufacturing, and logistics. It'll be interesting to see how major challenges are addressed including the high treatment costs and the need for innovative reimbursement models! #GeneTherapy #CGT #Investment

9

👁 The strategic vision that many in the biotech industry have anticipated is unfolding. On Monday, Fierce Biotech released its analysis of the 'smartest' pharma acquisitions, highlighting key moves that are reshaping the landscape. "As part of our ongoing commitment to innovation and growth, these strategic acquisitions allow us to be more agile, drive efficiency, and focus on bringing the most promising treatments to market as swiftly as possible," said a top industry analyst. 💸 The report detailed multiple high-profile deals, including the $14 billion buyout of Karuna, the $4.8 billion acquisition of Mirati, and the $4.1 billion deal to acquire RayzeBio. Each of these moves is seen as a step toward enhancing the acquiring companies' pipelines and expanding their capabilities. 👩‍🔬 Throughout 2024, LinkedIn has seen a buzz of activity, with several industry professionals discussing how these acquisitions are impacting their roles and the broader industry as a whole. The report also hinted at a shift towards smaller, strategic bolt-on acquisitions rather than large-scale buyouts, a trend that has been seen in recent industry moves. As we continue to monitor these developments, the message is clear: the biotech industry is evolving rapidly, with strategic acquisitions playing a pivotal role. Join the conversation—check out the article and share your thoughts on these smart acquisitions in the comments! Full article here: https://lnkd.in/dQM6P-2e

4

Access our advanced analytics support and boost efficiencies across the lifecycle of your trials, from selecting the best trial sites to faster recruitment. ⌚ Our systems have helped our clients begin trials weeks earlier with significant savings in project efficiencies. 👉 Discover Clinical Intelligence: https://lnkd.in/eK745Bde #Phastar #Data #ClinicalTrials #Analytics #Efficiency #DrugDevelopment

8

Is your business struggling to fill vacancies? Get in touch with us for all of your recruitment needs - ✉️ info@capilaux.com #recruitment #pharmaceutical #jobsearch #career #recruiter #employment #lifesciences #manufacturing #highlyregulatedindustries

1

Oncology clinical research sites often encounter intricate challenges in budgeting for complex trials. Join us to review common billable items often overlooked in budgeting processes through the SCRS Site Invoiceables Toolkit. Gain practical knowledge to empower your site to navigate budget negotiations. Register here ⇢ https://lnkd.in/drGxcv4e

5

Almac Clinical Technologies acquires Your Research to expand eClinical solutions for participants, sites and sponsors. Find out how you can be among the first to adopt these cutting-edge solutions: https://hubs.li/Q02_pq880

99

1 Comment

Did you know skipping reference checks can be costly? With busy schedules and tight deadlines, it can be tempting to rely solely on a candidate's provided information. However, doing so could lead to restarting the recruitment process from scratch. In a recent podcast, our Client Services Director James Inwood met with Pippa Hutchinson and they dived into the importance of vetting candidates to ensure they’re the right match for your team. Find out more in the episode: https://lnkd.in/eyRFrzCh #HiringTips #RecruitmentServices #ReferenceCheck #Recruitment #LifeSciences

7

Download your copy of Tech and Talent: The Future of Life Science, our latest industry e-book. This guide explores cutting-edge technological advancements and digital innovations that are transforming the life sciences industry. It also addresses the challenges businesses are facing and the skills gaps that demand a new approach to hiring. https://lnkd.in/ewWvJejS

9

Hiring Qualified Persons (QPs) is critical to maintaining high standards in industries like pharmaceuticals. Attracting top QP talent requires a strategic approach that highlights your organisation’s strengths and commitment to quality. Find out how here ⬇️ enquiries@assure-bio.com Dal Pawar #BiotechJobs #PharmaRecruitment #QualityAssurance #LifeSciences #HealthcareRecruitment #BiotechCareers

5

3 Comments

The pharmaceutical industry faces a landscape defined by unprecedented complexity and fierce competition. As companies strive for commercial success amidst these challenges, the imperative to adopt innovative strategies has never been more critical. From precision marketing to the transformative potential of artificial intelligence and the evolving role of real-world evidence (RWE) in market access, pharmaceutical leaders are redefining their approach to product launches. By harnessing technology, data-driven insights, and strategic alliances, organizations are poised not only to navigate these complexities but also to lead in delivering impactful healthcare solutions to global markets. Take a look at this article for more insights!

14

1 Comment

💉 Labcorp Launches New Global Trial Connect 💉 Labcorp, a global leader in laboratory services, has introduced Labcorp Global Trial Connect, a suite of central laboratory solutions designed to enhance clinical trial efficiency. This initiative focuses on investigator sites, where critical clinical research occurs. The suite includes several features: 🖥 Site enablement resources: These resources help identify new study opportunities, improve patient access and recruitment, and enhance diversity in clinical trials. 🖥 Supply readiness support: Labcorp aims to increase study startup efficiencies, reduce trial delays, and minimize supply and kit waste. 🖥 Site workflow facilitation: By integrating sample collection and tracking data, this feature provides visibility and actionable analytics to both sites and sponsors. It also reduces errors, queries, holds, and data revisions through eRequisition functionality. 🖥 Study management and investigator support: Labcorp offers 24/7 site support and on-demand tools and training to accelerate study startup and maintain study momentum. For more information go to https://lnkd.in/eweP-mX7 #clinicaltrial #contractresearch #labcorp #globaltrialconnect #CRO #studystartup #studies #trials #biopharma #lifescience

13